Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Johnson & Johnson to the U.S. Securities and Exchange Commission. The reporting period covers holdings as of March 31, 2026. The document details the company's equity securities holdings, specifically focusing on a portfolio of biotechnology and healthcare-related companies.
Key Financial Metrics and Holdings
The filing does not report Johnson & Johnson's consolidated revenue, profit, cash flow, or debt. Instead, it lists specific equity positions held by the company. The total value of the reported positions is approximately $30.8 million based on the sum of the "Value" column.
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Protagonist Therapeutics Inc. | 258,143,888 | $2,449,183 | Sole |
| Nanobiotix S.A. | 173,607,200 | $5,623,816 | Sole |
| CVRx, Inc. | 38,075,185 | $4,024,861 | Sole |
| MeiraGTx Holdings plc | 57,511,614 | $6,641,064 | Sole |
| Contineum Therapeutics Inc. | 25,847,999 | $1,979,173 | Sole |
| Fate Therapeutics, Inc. | 4,054,877 | $3,379,064 | Sole |
| Legend Biotech Corporation | 14,735,861 | $814,586 | Sole |
| Rapport Therapeutics, Inc. | 55,837,537 | $1,784,517 | Sole |
| Xencor, Inc. | 9,021,628 | $748,062 | Sole |
| Neumora Therapeutics, Inc. | 3,606,418 | $1,849,445 | Sole |
| Procept BioRobotics Corporation | 8,952,054 | $357,939 | Sole |
| Adicet Bio, Inc. | 155,125 | $22,779 | Sole |
| Nano-X Imaging Ltd. | 189,668 | $83,554 | Sole |
| Rallybio Corporation | 1,371,522 | $152,901 | Sole |
| Vor Biopharma, Inc. | 958,579 | $53,732 | Sole |
| Standard BioTools, Inc. | 311,967 | $311,967 | None |
Material Changes
The filing text does not provide comparative data for the prior quarter or year. Consequently, material changes in holdings versus the prior comparable period cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F is a regulatory disclosure of holdings and does not contain management commentary, financial guidance, or outlook for Johnson & Johnson. The filing includes a standard disclaimer stating that the SEC has not reviewed the information for accuracy or completeness. No specific risks or contingencies related to these specific holdings are detailed in the text provided.
Investor Verification Checklist
- Portfolio Scope: Verify if this list represents the entirety of Johnson & Johnson's biotech investments or only a specific subset (e.g., new purchases or specific fund mandates).
- Valuation Timing: Confirm the exact market prices used to calculate the "Value" column as of March 31, 2026, given the volatility of biotech stocks.
- Voting Rights: Note that Standard BioTools, Inc. is listed with "None" for voting authority, whereas all other listed positions have "Sole" voting authority.
- Strategic Intent: Investigate whether these holdings represent strategic investments, venture capital arms, or passive financial investments.